Rate My Professor Jennette Sakoff

Sakoff's research interests encompass breast cancer, cancer chemotherapy, drug development, dynamin, glioblastoma, and PP2A. She has co-authored over 138 journal articles and 35 conference papers, with notable publications including "Dynole-Based Dynamin Inhibitors as Novel Cytotoxic Agents" (ChemistrySelect, 2025), "2,3-Dihydroquinazolin-4(1H)-ones and quinazolin-4(3H)-ones as broad-spectrum cytotoxic agents and their impact on tubulin polymerisation" (RSC Medicinal Chemistry, 2024), "A novel naphthalimide that selectively targets breast cancer via the arylhydrocarbon receptor pathway" (Scientific Reports, 2020), "(Z)-2-(3,4-dichlorophenyl)-3-(1H-pyrrol-2-yl)acrylonitrile exhibits selective antitumor activity in breast cancer cell lines via the aryl hydrocarbon receptor pathway" (Molecular Pharmacology, 2018), and "Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues" (Investigational New Drugs, 2002). Her work has led to the development of agents targeting protein phosphatases, dynamin, clathrin, and the AhR pathway, with ANI-7 now commercially available. Sakoff has been principal investigator or team member on 35 grants totaling $3,607,747. Awards include Young Medical Researcher of the Year (2000) and Pulse Education Prize (2001). She delivers selected lectures in drug development.